Flexible assembly

Ypsomed has developed an auto-injector product family for a wide range of applications. The final assembly can be performed with an Assembly Lab System by Harro Höfliger.



The YpsoMate product family.

uto-injectors are devices with pre-filled syringes that enable patients to inject themselves. In recent years, there has been a strong increase in demand for these products – a trend that is likely to continue. This is because these devices are not only used for the treatment of various autoimmune diseases; currently, various biologics are under development that could be used, for example, as injections for the treatment of cancer, asthma and migraine. Also, many medicines for rare diseases

are generally injectable. In order to be able to meet this diversity with a high degree of flexibility, the Swiss company Ypsomed has developed the auto-injector platform YpsoMate. These devices are compatible with all common glass or polymer syringes with a filling volume of one or two milliliters. The platform approach simplifies the market launch of auto-injectors while at the same time enabling individual customization. The final assembly of smaller series of the YpsoMate product family can be per-

formed on Harro Höfliger's semi-automatic Assembly Lab system which can also be used for pen production. Batch sizes can be determined individually – which is beneficial, for instance, when producing high-priced devices for the treatment of rare diseases. If larger batches are desired, the Assembly Lab ensures a safe development of the product. All process parameters can be reliably transferred to production machines with higher outputs.



The final assembly of smaller series can be performed on the semi-automatic Assembly Lab system.

About Ypsomed

Ypsomed AG with headquarters in Burgdorf (Switzerland) is the leading, independent developer and manufacturer of user-friendly injection systems for self-medication. With innovative Swiss-made products such as pens, auto-injectors and large-volume patch injectors, Ypsomed meets all the demands that pharmaceutical enterprises make for self-injection.

